Summaryofselectedrepo

Summaryofselectedrepo

SUMMARY OF SELECTED REPORTABLE DISEASES, January-December, 2018 Case counts refer to confirmed and probable cases. Final data. The following morbidities have a count at least 2 times greater than their 5-year medians: Cryptosporidiosis; E. coli, Shiga toxin-producing; Mumps; Streptococcal Group A, invasive; Syphilis, Congenital; Syphilis, Early Latent; Syphilis, Late And Late Latent; Vibrio infection; The following morbidities have a count at least 2 times less than their 5-year medians: Haemophilus influenzae B, all ages; Meningococcal, invasive; Pertussis, confirmed and probable; West Nile virus; Syphilis, Congenital Cryptosporidiosis Syphilis, Early Latent Syphilis, Late And Late Latent Vibrio infection Streptococcal Group A, invasive Mumps E. coli, Shiga toxin-producing Syphilis, Primary And Secondary Rocky Mtn. Spotted Fever Gonorrhea Amebiasis Hepatitis A MRSA Chlamydia Coccidioidomycosis Streptococcus pneumoniae, invasive Giardiasis Salmonellosis Legionellosis Hepatitis B chronic Campylobacteriosis Listeriosis Shigellosis Hepatitis B acute Dengue Streptococcal Group B, invasive, infant <90 days Pertussis, confirmed and probable Haemophilus influenzae B, all ages West Nile virus Meningococcal, invasive -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 BELOW median Comparison of count to 5-year median ABOVE median The following morbidities are not shown, due to a count or 5-year median = 0: Carbapenem-resistant Enterobacteriaceae (CRE); Chikungunya; Hantavirus infection; Influenza; Measles; Zika; SUMMARY OF SELECTED REPORTABLE DISEASES Jan-December, 2018 1, 2 Case counts refer to confirmed and probable cases Jan-Dec Jan-Dec 5-year Median 2018 2017 Jan-Dec VACCINE PREVENTABLE DISEASES: Haemophilus influenzae , serotype b invasive disease, all ages 1 2 3 Haemophilus influenzae , serotype b, invasive disease, <5 years of age 1 2 3 Measles 0 0 3 Meningococcal infection, invasive 1 4 5 Mumps 15 34 7 Pertussis, probable and confirmed 239 420 517 Pertussis, confirmed cases only 135 262 287 ENTERIC DISEASES: Amebiasis 21 16 16 Campylobacteriosis 1,269 1,372 1,241 Cryptosporidiosis 203 112 62 E.coli , Shiga toxin-producing 296 166 148 Giardiasis 149 145 125 Listeriosis 6 8 6 Salmonellosis 1,149 875 1,010 Shigellosis 478 555 549 Vibrio infection 54 25 25 VIRAL HEPATITIDES: Hepatitis A 80 61 61 Hepatitis B, acute 30 41 41 Hepatitis B, non-acute 1,028 1,017 929 INVASIVE DISEASES: Legionellosis 83 74 74 Streptococcus pneumoniae 862 707 716 Streptococcus group A 758 614 351 Streptococcus group B in infants <90 days of age 40 63 60 Methicillin-resistant Staphylococcus aureus 1,529 1,355 1,178 VECTOR-BORNE & ZOONOTIC DISEASES: Chikungunya 0 0 4 Dengue 10 3 14 Hantavirus infection 0 2 4 Rocky Mountain spotted fever 38 27 23 West Nile virus infection 27 110 103 Zika 3 3 0 SEXUALLY TRANSMITTED DISEASES: Chlamydia 40,867 39,649 32,509 Gonorrhea 12,903 12,526 8,269 Syphilis, primary and secondary 1,052 943 588 Syphilis, early latent 899 621 357 Syphilis, late and late latent 1,245 830 556 Syphilis, congenital 61 31 14 ALSO OF INTEREST IN ARIZONA: Carbapenem-resistant Enterobacteriaceae (CRE)3 243 N/A N/A Coccidioidomycosis 7,478 6,885 6,101 1 These counts reflect the year reported or tested and not the date infected. 2 During 2018, the 5-year median includes cases reported 2013 through 2017. 3 Carbapenem-resistant Enterobacteriaceae (CRE) became reportable in 2018. Animal rabies stats can be found at https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/rabies/data/2018.pdf. FINAL DATA - report updated 7/18/2019.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us